Stock Snapshot

{{getFormattedValue(stockQuote.changesValueFormatted)}} ({{getFormattedValue(stockQuote.changesPercentFormatted)}}%)
{{stockQuote.onlyDateFormatted}} (At Close)
Previous Close
Today’s Open
Average Volume (10 days)
Day's Range
{{todayDetailedInformation.todaysLow}} - {{todayDetailedInformation.todaysHigh}}
Market Cap
52 Week Range
{{detailQuote.weekLow}} -{{detailQuote.weekHigh}}
Total Shares Outstanding
More Info

Latest Company Reports

Latest Press Releases

22nd Century Announces New Greenbutts Manufacturing Agreement for Innovative Plant-Based, Biodegradable Cigarette Filters


Corporate Overview

22nd Century Group, Inc. is a leading plant biotechnology company focused on technologies that alter the level of nicotine in tobacco plants through genetic engineering, gene-editing, and modern plant breeding. Our primary mission in tobacco is to greatly reduce the harm caused by smoking by bringing our reduced nicotine content tobacco cigarettes – containing 95% less nicotine than conventional cigarettes – to adult smokers in the U.S. and international markets.

Why Invest

Commercializing disruptive products utilizing advanced alkaloid plant technologies to improve health

VLN® 95% reduced nicotine content cigarettes are the world’s first and only combustible cigarettes to receive Modified Risk Tobacco Product (MRTP) authorization from the FDA
North America’s largest CDMO provider of hemp-derived active ingredients for the pharmaceutical and consumer goods industries

Latest Presentation

Investor Presentation May 2024
May 01, 2024

Latest Events

22nd Century Group First Quarter 2024 Results Call
May 15, 2024

22nd Century Group, Inc.
500 Seneca Street, Suite 507
Buffalo, NY 14204

Matt Kreps
22nd Century Group
Investor Relations

contact us by phone 214-597-8200
contact us by email mkreps@xxiicentury.com

Continental Stock & Transfer Company
1 State Street, 30th Floor
New York, NY 10004

contact us by phone 212-509-4000
contact us by email cstmail@continentalstock.com